UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

SUO 2025: Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk NMIBC Undergoing Radical Cystectomy

(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Reuben Ben-David discussing preoperative ctDNA predicting upstaging and recurrence in ...
UroToday

MRI-targeted Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Addressing Urology Disparities Through Community Partnerships and Institutional Collaboration - Samuel Washington

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Heterogeneous expression of BMP7, HIF-2α, Ki-67, and E-Cadherin in clear cell renal carcinoma: Prognostic implications based on tumor region.

The transforming growth factor-beta (TGF-β) signaling pathway plays a critical role in tumor development and includes bone morphogenetic proteins (BMPs). Among them, BMP7 is essential for renal ...
UroToday

ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Daniel Petrylak discussing initial results of a ...
UroToday

Non-Muscle Invasive Bladder Cancer

EAU 2024 trial design of SunRISe-3, TAR-200 plus cetrelimab or TAR-200 versus intravesical BCG, BCG-naive high-risk non–muscle-invasive bladder cancer, transure ...
UroToday

Regulatory Considerations in the BCG-Naïve Non-Muscle-Invasive Bladder Cancer Setting

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...
UroToday

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant ...

(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...
UroToday

ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
UroToday

SUO 2024: Mechanism of Action and Translation to the Clinic of Detalimogene Voraplasmid (EG-70) – A Novel, Investigational Non-Viral Immunotherapy for NMIBC

(UroToday.com) The 2024 SUO annual meeting included a bladder cancer session, featuring a presentation by Dr. Anthony Cheung discussing the mechanism of action and translation to the clinic of ...
UroToday

AUA 2023: Single Port Robotic Assisted Radical Prostatectomy, Technical Point of View

(UroToday.com) The 2023 American Urological Association (AUA) annual meeting held in Chicago, IL between April 28 and May 1st, 2023, was host to the Arab Association of Urology sectional session. Dr.